HHS Recovery Act Recipient Reporting Readiness Tool
Step 4. Review and Copy the Grant Awards Data
TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.
You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please e-mail our help desk at Readiness Help.
| Recipient Report: Grant or Loan | ||
| Prime Recipient |
| Reporting Information | ||
| Award Type | Award Number | Final Report |
| Grant | 5R01DA005477-20 | Recipient responsible for this data |
| Award Recipient Information | ||
| Recipient DUNS Number | Recipient Account Number | Recipient Congressional District |
| 004868105 | Recipient responsible for this data | 2 |
| Award Information | ||
| Funding Agency Code | Awarding Agency Code | Award Date |
| 7529 | 7529 | 06-01-2010 |
| Amount of Award | Sub Account Number for Program Source (TAS) | |
| $ 479,869 | Recipient responsible for this data | |
| Program Source (TAS)* | CFDA Number | |
| 750908 | 93.701 | |
| Total Number of Sub Awards to Individuals | Total Amount of Sub Awards to Individuals | |
| Recipient responsible for this data | Recipient responsible for this data | |
| Total Number of Payments to Vendors less than $25,000/award | Total Amount of Payments to Vendors less than $25,000/award | |
| Recipient responsible for this data | Recipient responsible for this data | |
| Total Number of Sub Awards less than $25,000/award | Total Amount of Sub Awards less than $25,000/award | |
| Recipient responsible for this data | Recipient responsible for this data | |
| Award Description | ||
| DESCRIPTION (provided by applicant): Drug abuse, addiction, and dependence remain major threats to public health. The 2005 National Survey on Drug Use and Health reports cocaine use in 2005 was similar to that in the previous three years. Recently, methamphetamine abuse became America's number one drug threat. At present, there are no FDA approvedmedications to treat cocaine or methamphetamine abuse. Development of new pharmacotherapies to treat cocaine, methamphetamine, and other stimulant addiction would be a major medical and societal breakthrough. This application is for continuation of support for our research directed toward the design and development of potential pharmacotherapies for treating stimulant abuse. Previous studies were highly successful. 3Beta-(4-Chlorophenyl-2Beta-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336) was designed and developed as an indirect dopamine agonist pharmacotherapy for cocaine addiction. Phase 1 clinical studies are planned for 2007. This research also led to other potential pharmacotherapies for cocaine addiction that warrant development. A novel strategy for treating methamphetamine and similar compounds of addiction developed in collaboration with Dr. Michael Owens (University of Arkansas) is the use of monoclonal antibodies, which will bind the drugs of abuse and alter their pharmacokinetic properties in a manner that reduces or eliminates drug use. L-Glutamic acid (glutamate) is the major excitatory neurotransmitter in the central nervous system. Several studies reported over the last few years suggest that metabotropic glutamate 5 (mGluR5) receptors play an important role in regulating the reinforcing actions of drugs of abuse. Importantly, the studies suggest that mGluR5 antagonists have potential as novel pharmacotherapies to treat addiction to cocaine and other drugs of abuse. The MERIT Award provided freedom to broaden the scope of my stimulant abuse research. This opportunity was used to initiate projects in the (1) development of monoclonal antibodies for use in treating methamphetamine abuse and (2) development of mGluR5 antagonists as potential pharmacotherapies to treat stimulant addiction. The specific aims of this competing continuation/renewal application are: (1) To design, synthesize, and couple methamphetamine haptens to appropriate proteins (BSA, OVA, others) for use in developing monoclonal antibodies as pharmacotherapies to treat methamphetamine and other stimulant addictions. (2) To design, synthesize, and develop novel mGluR5 antagonists as potential pharmacotherapies to treat cocaine and other drug addiction. (3) To continue on a limited basis our development of selected 3-phenyltropane analogs as second-generation pharmacotherapies to treat cocaine addiction. | ||
| Project Information | ||||||||||||||||||||||||||
| Project Name or Project/Program Title |
Project Status | Total Federal Amount ARRA Funds Received/Invoiced |
||||||||||||||||||||||||
| DESIGN AND DEVELOPMENT OF PHARMACOTHERAPIES FOR TREATING STIMULANT ABUSE | Recipient responsible for this data | Recipient responsible for this data | ||||||||||||||||||||||||
| Number of Jobs | Description of Jobs Created | |||||||||||||||||||||||||
| Recipient responsible for this data | Recipient responsible for this data | |||||||||||||||||||||||||
| Quarterly Activities/Project Description | ||||||||||||||||||||||||||
| Recipient responsible for this data | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| Total Federal Amount of ARRA Expenditure |
Total Federal ARRA Infrastructure Expenditure |
Infrastructure Contact Name | ||||||||||||||||||||||||
| Recipient responsible for this data | Recipient responsible for this data | Recipient responsible for this data | ||||||||||||||||||||||||
| Infrastructure Contact Email | Infrastructure Contact Phone | Infrastructure Contact Phone Ext. | ||||||||||||||||||||||||
| Recipient responsible for this data | Recipient responsible for this data | Recipient responsible for this data | ||||||||||||||||||||||||
| Infrastructure Contact Street Address 1 | Infrastructure Contact Street Address 2 | Infrastructure Contact Street Address 3 | ||||||||||||||||||||||||
| P.O. BOX 12194 | Not Available | Recipient responsible for this data | ||||||||||||||||||||||||
| Infrastructure City | Infrastructure State | Infrastructure ZIP Code+4 | ||||||||||||||||||||||||
| RSCH TRIANGLE PK | NC | 27709-2194 | ||||||||||||||||||||||||
| Infrastructure Purpose and Rationale | ||||||||||||||||||||||||||
| Recipient responsible for this data | ||||||||||||||||||||||||||
| Primary Place of Performance | ||
| Street Address 1 | Street Address 2 | City |
| BOX 12194, 3040 CORNWALLIS RD | Recipient responsible for this data | RESEARCH TRIANGLE PARK |
| State | Zip Code+4 | Congressional District |
| NC | 277092194 | Not Available |
| Country | ||
| US | ||
| Recipient Highly Compensated Officers | |||
| Prime Recipient Indication of Reporting Applicability | # | Officer Name | Officer Compensation |
| Recipient responsible for this data | 1 | Recipient responsible for this data | Recipient responsible for this data |
| 2 | Recipient responsible for this data | Recipient responsible for this data | |
| 3 | Recipient responsible for this data | Recipient responsible for this data | |
| 4 | Recipient responsible for this data | Recipient responsible for this data | |
| 5 | Recipient responsible for this data | Recipient responsible for this data | |
This concludes the current search.
To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool.
USE IN THE RECIPIENT REPORT
The information provided by this tool is baseline data that the Recipient should include in the Recipient Report that must be submitted to FederalReporting.gov beginning October 1, 2009. The data from this tool can be cut and pasted directly into the Recipient Report.
